483
CellTrans, Inc.FDA 483 - CellTrans, Inc. - May 06, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of CellTrans, Inc. in Chicago, IL, identified one observation related to clinical trial documentation. The firm, acting as a sponsor, failed to include the complete required ClinicalTrials.gov statement in informed consent documents for five subjects. This indicates a deficiency in adhering to regulatory requirements for clinical trial transparency and subject information.
Open in Dashboard
ID · 89bad219-38ce-44a8-81d3-1236f579e7a5